Omixon is a global molecular diagnostics company, empowering clinical labs with technologies to improve patient outcomes by commercializing disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.
We all need a little reassurance sometimes… In the past few years Next Generation Sequencing has conquered immunology labs all around the world and is actively used in both research and diagnostics. But how was it possible to develop and …more
Omixon is pleased to announce that HLA Twin 1.1.4 version is now available. This latest version provides users with an updated interface as well as many improvements meant to help them easily use the software with even greater efficiency.